Shareholder group nominates slate of director candidates for Opus Genetics

Mina Sooch, founder of Ocuphire Pharma, now known as Opus Genetics (IRD), announced that she has nominated a slate of seven candidates for election to the Company’s Board of Directors at the upcoming Annual Meeting of Stockholders. Collectively, the Restore Value Slate beneficially owns approximately 4.1% of the Company’s outstanding shares of common stock. The group said, “If elected, the Nominees will bring the leadership, accountability, and transparency necessary to restore long-term shareholder value without further dilution. The Restore Value Slate is committed to addressing the critical governance and operational failures that have persisted under the current Board. The Company has scheduled the Annual Meeting significantly earlier than in previous years, setting the date for April 30, 2025. This accelerated timeline shortens the typical window for shareholder engagement ahead of this pivotal election. Stockholders are encouraged to review the Restore Value Slate’s materials as they become available.” The slate consists of Mina Sooch, Mark Ravich, John Weber, Michael Burrows, Carolyn Cassin, Martin Dober and Vitalie Stelea.